Cytek Biosciences, Inc. (CTKB) celebrated the first anniversary of its Singapore manufacturing and service center on March 9, 2026. The 8,500‑square‑foot facility, which opened on March 9, 2025, has become a regional hub for production, logistics, and customer support across the Asia‑Pacific and worldwide.
The Singapore site has expanded its manufacturing capacity, shortened delivery times, and strengthened supply‑chain resilience amid geopolitical and tariff pressures. It also hosts a dedicated service and training center that provides hands‑on access to Cytek instruments and technical expertise for local customers.
CEO Wenbin Jiang said, “Establishing operations in Singapore has been a transformative step for Cytek. In just one year, the facility has strengthened our manufacturing footprint, improved supply chain agility, and deepened our engagement with customers across APAC.” The milestone underscores the company’s commitment to scaling its Full Spectrum Profiling platform and supporting its expanding installed base in the region.
Cytek’s financial performance in recent periods highlights the broader context for the facility’s impact. In 2024, the company generated $200.5 million in revenue, a 3.9% increase over 2023, but recorded a net loss of $6.0 million. The following year, revenue rose modestly to $201.5 million, while the net loss widened to $66.5 million, reflecting higher operating expenses and investment in growth initiatives. Management has guided 2025 revenue to $196–$210 million, signaling confidence in the company’s ability to generate incremental sales from its expanded manufacturing footprint.
The Singapore hub supports Cytek’s focus on recurring revenue streams, including service and reagents, and complements recent product launches such as the Aurora Evo system (May 2025) and the Muse Micro cell analyzer (awarded 2025). These launches reinforce the company’s Full Spectrum Profiling platform and expand its market reach, while the new facility provides the production capacity needed to meet growing demand.
By diversifying its manufacturing base and improving supply‑chain agility, Cytek aims to reduce delivery times and mitigate geopolitical risks that have pressured the industry. The company’s balanced strategy, which emphasizes sustainable growth and profitability, positions it to capitalize on the fast‑growing biomedical research market in Asia‑Pacific while maintaining a resilient global supply chain.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.